Bonemas D 70/2800 IU Tab. -

Tablet

Pack Size : 10 Tablet x 1 Strip

Generics : Alendronic Acid + Vitamin D3

Manufacturer : Incepta Pharmaceuticals Ltd.

Best Price * TK 300.00

* Delivery will be done in Dhaka city only.

Alternative Product

More Information About - Bonemas D 70/2800 IU Tab. -

Description

Generic Name

Alendronic Acid + Vitamin D3

Precaution

Upper GI disorders (discontinue if symptoms worsen); history of ulcers, active GI bleeding. Correct vitamin D and calcium deficiency before starting therapy. To be taken half an hr before breakfast and remain upright for at least 30 minutes after admin. Not recommended for use in patients with CrCl <35 ml/min.

Indication

Osteopetrosis, postmenopausal osteoporosis, Paget's disease of bone

Contra Indication

Hypocalcaemia; oesophageal abnormalities and factors which delay oesophageal emptying; severe renal impairment; hypersensitivity; inability to stand or sit upright for <30 min. Pregnancy, lactation.

Dose

N/A

Side Effect

The most common side-effect is digestive reactions. These reactions include irritation, inflammation, or ulcers of the esophagus, which may sometimes bleed. This may occur especially if patients do not drink a full glass of water or if they lie down in less than 30 minutes or before their first food of the day. Less common side-effects are nausea, vomiting, a full or bloated feeling in the stomach, constipation, diarrhea, black or bloody stools, gas, headache, a changed sense of taste, and bone, muscle, or joint pain.

Pregnancy Category

Name : Not Classified

Description

FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

Alendronic acid reduces bone resorption by inhibiting the action of osteoclasts.

Interaction

Concomitant iron, calcium supplements and antacids hinder alendronate absorption. Concomitant aspirin or NSAIDs may increase the incidence of adverse GI effects.

Pregnancy Category Note

Alendronic Acid Pregnancy Available data on use in pregnant women insufficient to inform a drug-associated risk of adverse maternal or fetal outcomes; discontinue when pregnancy recognized. Lactation Not known whether drug present in human breast mild, affects milk production or has effects on infants Consider developmental and health benefits of breastfeeding along with mother?s clinical need for therapy and any potential effects on breastfed child from drug or underlying maternal condition Vitamin D3 Pregnancy There are no adequate and well-controlled studies in pregnant women Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus Animal studies Calcifediol has been shown to be teratogenic in rabbits when given in doses 8-16 times the human dose of 60 mcg/day, based on body surface area Lactation Limited data suggest calcifediol is poorly excreted in human milk; caution if administered to a breastfeeding female

Adult Dose

Treatment of osteoporosis in postmenopausal women: One tablet once weekly. Treatment to increase bonemass in men with osteoporosis: One tablet once weekly. Hepatic Impairment No dosage adjustment needed.

Child Dose

N/A

Renal Dose

Dosing in elderly and renal insufficiency: No dosage adjustment is necessary for the elderly or for patients with mild-to-moderate renal insufficiency (creatinine clearance 35 to 60 mL/min). CrCl (ml/min) <35 Not recommended.

Administration

N/A

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.